Related Experiment Videos
Natriuretic peptides and myocardial ischaemia
1Department of Basic Science, The Royal Veterinary College University of London, Royal College Street, NW1 0TU London, United Kingdom. gfbaxter@rvc.ac.uk
Basic Research in Cardiology
|February 14, 2004
Summary
Brain natriuretic peptide (BNP) release during myocardial ischemia offers cardioprotection by activating signaling pathways that limit tissue damage. BNP may also suppress adverse cardiac remodeling after infarction, suggesting therapeutic potential.
Area of Science:
- Cardiology
- Molecular Biology
- Physiology
Background:
- Myocardial ischemia triggers rapid release of brain natriuretic peptide (BNP) from ventricular myocardium.
- Natriuretic peptides exhibit pleiotropic effects, including attenuation of ischemic injury.
Purpose of the Study:
- To investigate the role of natriuretic peptides in myocardial ischemia and reperfusion.
- To explore the mechanisms of cytoprotection and long-term effects of BNP in infarcted myocardium.
Main Methods:
- Analysis of BNP release in experimental and clinical myocardial ischemia.
- Investigation of signaling pathways involving natriuretic peptide receptor/cGMP and ATP-sensitive K(+) channels.
- Evaluation of long-term effects of natriuretic peptide upregulation post-myocardial infarction.
Main Results:
- BNP release is rapid during myocardial ischemia.
- Natriuretic peptides limit infarct size during ischemia and reperfusion via cGMP and K(+) channel activation.
- Chronic BNP elevation may suppress myocyte and fibroblast growth, counteracting pro-hypertrophic mediators.
Conclusions:
- Acute and chronic actions of natriuretic peptides in myocardial ischemia suggest therapeutic benefits.
- BNP may be beneficial in managing acute coronary syndromes and optimizing post-infarction remodeling.